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PLipid Reduction Therapy
Statins, Low-Density
Lipoprotein Cholesterol, and Risk of Cancer
Alawi A. Alsheikh-Ali, MD,*† Thomas A. Trikalinos, MD,* David M. Kent, MD, MS,*
Richard H. Karas, MD, PHD†
Boston, Massachusetts
Objectives We sought to assess whether statin-mediated reductions in low-density lipoprotein cholesterol (LDL-C) are asso-
ciated with an increased risk of cancer.
Background We recently reported an inverse association between on-treatment LDL-C levels and incident cancer in statin-
treated patients enrolled in large randomized controlled trials, raising concern that LDL-C lowering by statins
may increase cancer risk. However, meta-analyses suggest a neutral overall effect of statins on incident cancer.
Methods A systematic literature search identified 15 eligible randomized controlled trials of statins with 1,000 person-
years of follow-up that provided on-treatment LDL-C levels and rates of incident cancers (19 statin and 14 con-
trol arms, 437,017 person-years cumulative follow-up, and 5,752 incident cancers).
Results In the statin arms, meta-regression analysis demonstrated an inverse association between on-treatment LDL-C
and incident cancer, with an excess of 2.2 (95% confidence interval: 0.7 to 3.6) cancers per 1,000 person-years
for every 10 mg/dl decrement in on-treatment LDL-C (p  0.006). The corresponding difference among control
arms was 1.2 (95% confidence interval: 0.2 to 2.7, p  0.09). Compared with the control arms, the statin re-
gression line was significantly shifted leftward, such that similar rates of incident cancer were associated with
lower on-treatment LDL-C (p  0.05). Meta-regression demonstrated that statins lack an effect on cancer risk
across all levels of on-treatment LDL-C.
Conclusions There is an inverse association between on-treatment LDL-C and incident cancer. However, statins, despite pro-
ducing marked reductions in LDL-C, are not associated with an increased risk of cancer. (J Am Coll Cardiol
2008;52:1141–7) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.037b
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an a recently published analysis, we examined the rela-
ionship between the degree of low-density lipoprotein
holesterol (LDL-C) lowering and adverse events in large
andomized controlled trials (RCTs) of hydroxymethyl-
lutaryl coenzyme A reductase inhibitors (statins) (1).
uring the peer review process, we were asked by the
ditors and reviewers to include cancer in the analysis,
nd in doing so observed a significant inverse relationship
etween on-treatment levels of LDL-C and newly diag-
osed cancer in statin-treated patients (1,2). The ob-
erved relationship in statin RCTs is consistent with
rior epidemiologic observations of an inverse association
rom the *Institute for Clinical Research and Health Policy Studies and †Molecular
ardiology Research Institute and Division of Cardiology, Department of Medicine,
ufts Medical Center and Tufts University School of Medicine, Boston,
assachusetts. Dr. Alsheikh-Ali is currently a recipient of a faculty development
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fizer. Dr. Karas has received honoraria from Merck and Abbott, and research
upport from AstraZeneca.s
Manuscript received March 4, 2008; revised manuscript received May 27, 2008,
ccepted June 6, 2008.etween serum cholesterol levels and incident cancer (3).
hese findings raised concern that lowering LDL-C with
tatins may decrease the risk of cardiovascular events at
he expense of an increased risk of cancer. In contrast to
hese findings, meta-analyses of randomized statin trials
ave not detected any clinically meaningful effect of
tatins on cancer incidence (4 – 6).
See pages 1148 and 1150
In the present study, we examine this apparent paradox
y simultaneously considering potential effects of statin
se and on-treatment LDL-C levels on cancer risk. First,
e expand upon the previously reported association
etween incident cancers and low on-treatment LDL-C
evels in statin-treated patients by accounting for poten-
ial confounders in multivariable analyses. Second, we
xamine the relationship between on-treatment LDL-C
nd incident cancer in the control arms of statin RCTs
nd compare this relationship with that found in the
tatin-treated patients. Finally, we perform a meta-
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Statins, Cholesterol, and Cancer September 30, 2008:1141–7analysis/meta-regression of the
effects of statin versus control
therapy on cancer incidence, while
accounting for on-treatment
LDL-C levels.
Methods
Trial inclusion. Eligible studies
were RCTs of statin therapy
published in the English litera-
ure with at least 1,000 person-years of follow-up that
eported both on-treatment LDL-C levels and incidence of
ewly diagnosed cancer during the study follow-up period.
e performed a MEDLINE search to identify potential
rials published up to July 2007 that would meet our
nclusion criteria. Our electronic search strategy included
he following terms: hydroxymethylglutaryl-CoA reductase
nhibitors, statin, lovastatin, simvastatin, pravastatin, ator-
astatin, cerivastatin, fluvastatin, or rosuvastatin. Citations
ere limited using the terms human, English language, and
andomized controlled trial. Additionally, we reviewed the
eference lists of published meta-analyses of statin trials to
nsure that all appropriate trials were included (4–6).
ata extraction. For each eligible study, the following
ariables were extracted from the published manuscript: the
pecific statin used and dose, number of patients in the
tatin and control arms, duration of follow-up, baseline and
n-treatment serum LDL-C levels, and number of patients
ith newly diagnosed cancer over the period of follow-up.
ince nonmelanoma skin cancers were not consistently
ecorded in all trials, these were not included in the present
nalysis. In addition, for each trial arm, the following
aseline patient characteristics were recorded: age, gender,
moking status, history of diabetes mellitus or hypertension,
nd body mass index. For categorical variables (e.g., hyper-
ension, smoking status) the proportion of patients with
uch characteristics at baseline was recorded. For continuous
ariables (e.g., age, body mass index), the mean or median
as reported in the published manuscript) was recorded.
erson-years of follow-up for each study arm were calcu-
ated by multiplying the reported follow-up in years by the
umber of persons in each arm. Risk of incident cancer was
stimated by dividing the number of persons with newly
iagnosed cancer over person-years of follow-up, and ex-
ressed per 1,000 person-years.
n-treatment LDL-C and incident cancer in the statin
rms. The relationship between on-treatment serum
DL-C levels and cancer risk in the statin arms was first
ssessed using univariable meta-regression (see Statistical
ethods section). Similarly, we assessed the relationship
etween cancer risk and each of the following baseline
haracteristics: mean age, proportion of male subjects,
roportion smoking, proportion with diabetes mellitus,
roportion with hypertension, and mean body mass index.
Abbreviations
andAcronyms
CI  confidence interval
IRR  incidence rate ratio
LDL-C  low-density
lipoprotein cholesterol
RCT  randomized
controlled trialach of the baseline factors that showed a significant wnivariable association with incident cancer was used to
djust the meta-regression of incident cancer risk and
n-treatment LDL-C in a multivariable model.
n-treatment LDL-C and incident cancer in the control
rms. To understand the role of statin therapy on the
bserved association between LDL-C levels and cancer risk,
e assessed the same relationship (i.e., on-treatment
DL-C and risk of cancer) in the control arms of the statin
rials. This offers an opportunity to observe the association
f LDL-C and incident cancer in a population otherwise
omparable to the statin arms, except for lack of statin
herapy. We then compared the association of on-treatment
DL-C levels with cancer risk in the control arms with that
n the statin arms (see Statistical Methods section).
tatin’s effect on cancer risk adjusting for on-treatment
DL-C levels. While several meta-analyses have shown
o significant effect of statin therapy on risk of cancer, it
emains possible that the overall neutral effect observed in
he previously published meta-analyses obscures an under-
ying heterogeneity of statin effect on cancer risk based on
evels of on-treatment LDL-C. For example, if statins
ncrease the risk of cancer at very low LDL-C levels but
ave an antineoplastic effect at higher levels (or vice versa),
hen one would expect an overall neutral effect in a conven-
ional meta-analysis, unless on-treatment LDL-C levels are
ccounted for. To directly address this possibility, we
erformed a meta-analysis/meta-regression, examining the
ffect of statin therapy across the range of on-treatment
DL-C levels in each arm (see Statistical Methods section).
tatistical methods. META-REGRESSIONS OF STATIN OR
ONTROL ARMS FROM LARGE RCTS. In the main analyses,
e assumed that incident cancer rates per trial arm were
ormally distributed. We used random effects meta-
egressions to evaluate the association between incident
ancer rates and average on-treatment LDL-C levels or
ther baseline variables, as described in the previous text (7).
hese analyses take into account both within- and between-
rm variability. We performed further analyses assuming
hat incident cancers follow a Poisson distribution over the
ollow-up period of each trial (8). Specifically, we used
oisson regressions with robust standard error estimation,
nd Bayesian random effects Poisson meta-regressions (9).
o contrast the association of on-treatment LDL-C levels
o cancer risk in the statin versus control arms, we compared
he slopes of the 2 regression lines, and used the Chow test
o assess whether regression coefficients estimated over
tatin arms are equal to the coefficients estimated over
ontrol arms (i.e., whether the regression lines were identi-
al or not) (10).
ETA-ANALYSIS ADJUSTING FOR ON-TREATMENT LDL-C
EVELS. We calculated the summary effects of statin versus
ontrol on incident cancer rates before and after adjustments
or average on-treatment LDL-C levels per trial arm. These
nalyses were again performed in a meta-regression frame-
ork, by including indicator variables describing treatment
a
L
i
c
t
C
c
m
w
P
C
p
a
t
a
i
b
B
t
c
O
R
E
w
h
s
f
o
1
i
f
T
a
a
o
c
a
o
o
t
T
2
t
O
a
c
l
c
1
(
s
i
t
t
r
b
e
c
C
0
p
O
a
r
d
s
e
c
m
c
t
1
B

t
L
c
t
o
p
c
l
T
t
s
c
d
t
o
s
p
h
s
0
i
t
t
D
M
d
L
t
s
i
L
c
1143JACC Vol. 52, No. 14, 2008 Alsheikh-Ali et al.
September 30, 2008:1141–7 Statins, Cholesterol, and Cancerllocation and parent trial, the average on-treatment
DL-C level in each arm, and treatment by LDL-C level
nteraction. We also performed the corresponding hierar-
hical random effects Poisson meta-regression analyses in
he Bayesian framework.
Analyses were performed in Intercooled Stata 8.2 (Stata
orp., College Station, Texas). All p values are 2-tailed and
onsidered significant at the 0.05 level. No adjustments for
ultiple comparisons were performed. Bayesian analyses
ere performed in OpenBUGS and JAGS 0.98 (Martyn
lummer, 2005) programs that use Markov Chain Monte
arlo to obtain posterior distributions of the modeled
arameters (11). Noninformative prior distributions were
ssigned to the cancer incidence rate and its variance, and
he coefficient of average on-treatment LDL-C. After visual
ssessment for convergence, we based results on 20,000
terations using 2 Markov Chain Monte Carlo chains, a
urn in of 10,000 iterations, and a thinning interval of 5.
ecause the results of Bayesian analyses are posterior dis-
ributions, we describe them using their median and a 95%
redibility interval (from the 2.5 to 97.5 percentile). See the
nline Appendix for further details.
esults
ligible trials. Our search yielded 2,026 citations, which
ere screened at the abstract level. Of these, 1,319 citations
ad 1,000 person-years of follow-up, 235 were not of a
tatin study, and 433 were not RCTs. Accordingly, 39
ull-text manuscripts were retrieved for detailed evaluation,
f which 24 were eventually excluded for having less than
,000 person-years of follow-up or for not reporting cancer
ncidence. Therefore, a total of 15 statin RCTs were eligible
or inclusion in the present analysis (Table 1) (12–27).
hese included 19 statin treatment arms and 14 control
rms. There were a total of 51,797 statin-allocated patients
nd 45,043 control-allocated patients followed over a mean
f 4.4 1.4 years (range of follow-up: 0.9 to 6.1 years). The
umulative exposure was 224,886 person-years in the statin
rms and 212,131 person-years in the control arms. A total
f 5,752 patients with incident cancer were included. The
n-treatment LDL-C levels ranged from 89 to 142 mg/dl in
he statin arms and 121 to 192 mg/dl in the control arms.
he incidence of newly diagnosed cancer ranged from 3.9 to
6.5 per 1,000 person-years in the statin arms and from 6.0
o 23.7 per 1,000 person-years in the control arms.
n-treatment LDL-C and incident cancer in the statin
rms. In univariable meta-regressions, there was a signifi-
ant inverse relationship between on-treatment LDL-C
evels and incident cancer in the statin arms, with 2.2 (95%
onfidence interval [CI]: 0.7 to 3.6) incident cancers per
,000 person-years for every 10 mg/dl decrement in LDL-C
p  0.006) (Fig. 1). In similar univariable analyses in the
tatin arms, there was a significant relationship between
ncident cancer and age (p  0.031) and history of hyper-
ension (p  0.049). In multivariable models, the associa- cion between on-treatment LDL-C and incident cancer
emained significant after adjusting for any of the available
aseline variables (Table 2). Results from Poisson fixed
ffects as well as Bayesian random effects regressions yielded
onsistent findings (incidence rate ratio [IRR]: 1.18 [95%
I: 1.09 to 1.27] per 10 mg/dl decrement in LDL-C, p 
.001, and IRR: 1.20 [95% credibility interval: 1.08 to 1.33]
er 10 mg/dl decrement in LDL-C, respectively).
n-treatment LDL-C and incident cancer in the control
rms. In univariable analyses, there was also an inverse
elationship between on-treatment LDL-C levels and inci-
ent cancer in the control arms of the statin trials, albeit not
tatistically significant in the linear meta-regressions. We
stimated an excess of 1.2 (95% CI: 0.2 to 2.7) incident
ancers per 1,000 person-years for every 10 mg/dl decre-
ent in LDL-C (p  0.09) (Fig. 1). However, the
orresponding results were highly statistically significant in
he Poisson meta-regressions (IRR: 1.11 [95% CI: 1.06 to
.16], p  0.001), and were similarly highly significant in
ayesian analyses (IRR: 1.12 [95% credibility interval:
1.00 to 1.26] per 10 mg/dl decrement of LDL-C). While
he slopes of the regression lines associating on-treatment
DL-C and risk of cancer were similar in the statin
ompared with those in the control arms (p 0.33), overall,
he 2 regression lines were significantly different from each
ther (Chow test p  0.049 for linear meta-regressions and
 0.001 for Poisson meta-regressions) (Fig. 1). As such,
ompared with control subjects, statin-treated patients had
ower levels of LDL-C at similar levels of cancer risk.
he effect of statins on cancer risk adjusting for on-
reatment LDL-C levels. In unadjusted meta-analyses,
tatin use was not associated with an increase in cancer rates
ompared with that seen in the control arms (incident rate
ifference 0.0 cancers per 1,000 person-years; 95% CI:0.7
o 0.7, p  0.99). The same was true when we adjusted for
n-treatment LDL-C in each trial and each arm: the
ummary incident rate difference was 0.2 cancers per 1,000
erson-years (95% CI: 5.1 to 5.6, p  0.92). The
ierarchical Bayesian adjusted meta-analysis yielded very
imilar findings (IRR: 1.02 with 95% credibility interval:
.95 to 1.10). The neutral effect of statin therapy on
ncident cancer was consistent across all levels of on-
reatment LDL-C levels (p  0.73 for the effect of on-
reatment LDL-C on statin-associated cancer risk) (Fig. 2).
iscussion
ain findings. The current analysis of large statin RCTs
emonstrates an inverse association between on-treatment
DL-C levels and incident cancer in statin-treated patients
hat persisted after accounting for patient age, gender,
moking, diabetes mellitus, hypertension, and body mass
ndex. Similarly, a relationship between on-treatment
DL-C levels and incident cancer was also observed in
ontrol populations not treated with statins. Importantly,
omparison of the association between on-treatment
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Statins, Cholesterol, and Cancer September 30, 2008:1141–7DL-C and risk of cancer in the statin-treated versus
ontrol patients demonstrated that the statin line was
ignificantly shifted horizontally to the left (Fig. 1). In this
ay, compared with control patients, statin-treated patients
chieve lower levels of LDL-C while maintaining similar
isks of cancer. In addition, we expanded on the results of
reviously published meta-analyses looking for relationships
etween statin therapy and cancer by adjusting for on-
reatment LDL-C levels. We observed that the previously
eported overall neutral effect of statins on cancer risk holds
rue for any given level of on-treatment LDL-C (Fig. 2).
haracteristics of Large Randomized Controlled Statin Trials Includ
Table 1 Characteristics of Large Randomized Controlled Statin
Study (Ref. #) Year
Follow-Up
(yrs)
Study Arms
(n)
On-Treatmen
LDL-C
(mg/dl)
EXCEL (12,13) 1991 0.9 L 20mg QD (1,642) 137
L 20mg BID (1,646) 119
L 40mg QD (1,645) 126
L 40mg BID (1,649) 108
Placebo (1,663) 181
4S (14) 1994 5.4 S 20–40mg QD (2,221) 122
Placebo (2,223) 192
WOSCOPS (15) 1995 4.9 P 40mg QD (3,302) 142
Placebo (3,293) 192
CARE (16) 1996 5 P 40mg QD (2,081) 97
Placebo (2,078) 135
Post-CABG (17) 1997 4.3 L 40–80mg QD (676) 93
L 2.5–5mg QD (675) 136
AFCAPS/Tex
CAPS (18)
1998 5.2 L 20–40mg QD (3,304) 115
Placebo (3,301) 156
LIPID (19) 1998 6.1 P 40mg QD (4,512) 113
Placebo (4,502) 150
KLIS (20) 2000 5 P 10–20mg QD (2,219) 135
Conventional (1,634) 144
GISSI Prevenzione
(21)
2000 1.9 P 20–40mg QD (2,138) 129
Control (2,133) 147
LIPS (22) 2002 3.9 F 80mg QD (844) 96
Placebo (833) 147
HPS (23) 2002 5 S 40mg QD (10,269) 89
Placebo (10,267) 129
PROSPER (24) 2002 3.2 P 40mg QD (2,888) 107
Placebo (2,913) 148
ALLHAT-LLT (25) 2002 4.8 P 40mg QD (5,170) 104
Usual care (5,185) 121
ALERT (26) 2003 5.1 F 40mg QD (1,050) 108
Placebo (1,052) 147
MEGA (27) 2006 5.3 P 10–20mg QD diet
(3,866)
128
Diet only (3,966) 151
ear refers to publication year. Target dose is in milligrams (mg).
AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosis Prevention Study; ALERT  As
reatment to Prevent Heart Attack Trial; BID twice daily; BMI body mass index; CARE Cholest
ISSI Prevenzione  Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico; HP
ollow-up; KLIS  Kyushu Lipid Intervention Study; L  lovastatin; LDL-C  low-density lipoprotein
ntervention Prevention Study; MEGAManagement of Elevated Cholesterol in the Primary Prevent
ypass Graft trial; PROSPER  Prospective Study of Pravastatin in the Elderly at Risk; QD  once
imvastatin Survival Study.aken together, these findings indicate that despite the sbserved inverse association between on-treatment LDL-C
evels and incident cancer, the LDL-C–lowering effect of
tatins is not associated with an increased risk of cancer, at
east over the time frame evaluated here.
The present analysis offers a novel contribution by exam-
ning the association of LDL-C and cancer in control
ohorts and comparing it with the one we recently reported
n statin-treated patients (1). In doing so, it addresses the
pparent paradox between the observed inverse association
f LDL-C levels and incident cancer rates and the prior
eta-analyses of statin trials. The current findings demon-
the Present Analysis
s Included in the Present Analysis
ncident
ancer
Age
(yrs)
Gender
(% Male)
Smoking
(%)
Diabetes
Mellitus
(%)
Hypertension
(%)
BMI
(kg/m2)
18 56 60 18 1 41 NR
8 56 58 18 1 40 NR
20 56 59 18 1 38 NR
18 55 59 18 1 38 NR
12 56 58 18 1 41 NR
90 59 82 24 5 26 26
96 59 81 27 4 26 26
116 55 100 44 1 16 26
106 55 100 44 1 15 26
172 59 86 21 14 42 28
161 59 86 21 15 43 28
48 62 92 12 NR NR NR
42 61 93 11 NR NR NR
252 58 85 13 3 22 27
259 58 85 12 2 22 27
379 62 83 9 9 41 NR
399 62 83 10 9 42 NR
77 58 100 38 22 44 24
55 58 100 41 24 42 24
16 60 87 12 13 36 26
25 60 86 11 14 37 27
46 60 84 25 14 39 27
49 60 83 28 10 38 26
814 63 75 14 29 41 NR
803 63 75 14 29 41 NR
245 75 48 26 11 62 27
199 75 48 28 11 62 27
378 66 51 23 36 100 30
369 66 51 23 34 100 30
108 50 67 19 19 76 26
127 50 65 18 19 74 26
119 58 32 21 21 42 24
126 58 31 20 21 42 24
nt of Lescol in Renal Transplantation trial; ALLHAT-LLT  Antihypertensive and Lipid-Lowering
d Recurrent Events trial; EXCEL Expanded Clinical Evaluation of Lovastatin study; F fluvastatin;
art Protection Study; Incident cancer  number of patients with newly diagnosed cancer during
terol; LIPID  Long-Term Intervention with Pravastatin in Ischemic Disease study; LIPS  Lescol
up of Adult Japanese study; NR not reported; P pravastatin; Post-CABG Post Coronary Artery
S  simvastatin; WOSCOPS  West of Scotland Coronary Prevention Study; 4S  Scandinavianed in
Trial
t
I
C
sessme
erol an
S  He
choles
ion Gro
daily;trate that despite the inverse association between LDL-C
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September 30, 2008:1141–7 Statins, Cholesterol, and Cancerevels and incident cancer, lowering of LDL-C with statins
i.e., a leftward shift in the horizontal LDL-C axis) is not
ccompanied by an increased risk of cancer (i.e., no vertical
hift along the cancer incidence axis). This supports the
otion that lowering LDL-C with statins does not contrib-
te etiologically to cancer. If lowering LDL-C were causally
elated to cancer, one would have expected an upward shift
n cancer risk along the same regression line in statin-treated
atients.
The interpretation of these findings and their implica-
ions for understanding the observed inverse association
etween on-treatment LDL-C levels and incident cancer
Figure 1 Relationship Between On-Treatment LDL-C Levels
and Incident Cancer in the Statin and Control Arms
Each arm from each trial is considered an independent cohort of statin-treated
or control individuals and is represented by an empty circle (with size propor-
tional to each arm’s weight in the meta-regressions). Note how statin cohorts
(arms) are shifted toward lower on-treatment low-density lipoprotein cholesterol
(LDL-C) levels, while corresponding to the same range of incident cancer rates.
Note the LDL-C scale on the horizontal axis.
Relationship Between On-Treatment LDL-C Leve
Table 2 Relationship Between On-Treatmen
Meta-Regression
Incid
for
On-Trea
Unadjusted
Adjusted for
Average age
Proportion of male subjects
Proportion of smokers
Proportion with diabetes mellitus
Proportion with hypertension
Average body mass indexLDL-C  low-density lipoprotein cholesterol.emain complex, as association studies such as those pre-
ented here do little to provide mechanistic insight. The
ain unanswered question is whether this association re-
ects an etiologic role for lower LDL-C levels in cancer
evelopment. The most straightforward interpretation of
ur findings supports the conclusion that LDL-C levels do
ot directly affect cancer risk. One potential explanation for
his is that the observed associations occur by chance,
hough the consistency of reports of significant inverse
ssociations between cholesterol levels and cancer risk from
pidemiologic studies makes this seem less likely. However,
DL-C levels might be influenced by an unknown con-
ounder that itself is related to cancer risk, while LDL-C
evels per se are not, or, alternatively, statins might lower
otal LDL-C levels without altering potentially oncogenic
DL sub-particles, and in this manner lower total LDL-C
evels without affecting the risk of cancer. The current
ndings do not, however, entirely exclude the possibility of
n etiologic role for lower LDL-C levels on cancer risk. For
Figure 2 Risk of Cancer in Statin Versus Control
Cohorts for Any Given Level of On-Treatment LDL-C
Each trial is represented by an empty circle (with size proportional to its
weight in the meta-regressions). The slope of the regression line represents
the extent to which the incidence rate ratio for cancer depends on the on-treat-
ment low-density lipoprotein cholesterol (LDL-C) level in the statin arms (p 
0.73 for the effect of on-treatment LDL-C on the incidence rate ratio for cancer
in statin vs. control cohorts). Note the LDL-C scale on the horizontal axis.
d Incident Cancer
-C Levels and Incident Cancer
ncers per 1,000 Person-Years
0 mg/dl Lower Increment of
LDL-C (95% Confidence Interval) p Value
2.2 (0.7–3.6) 0.006
1.8 (0.3–3.2) 0.021
2.1 (0.6–3.6) 0.009
2.2 (0.6–3.8) 0.011
2.7 (0.8–4.5) 0.008
2.1 (0.4–3.8) 0.021
2.7 (0.9–5.3) 0.044ls an
t LDL
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Statins, Cholesterol, and Cancer September 30, 2008:1141–7xample, statins’ effects on cancer may require longer dura-
ions of follow-up than observed in the RCTs examined
ere, or, alternatively, a pro-neoplastic effect of statin-
ediated LDL-C lowering is offset by an antineoplastic
ffect of statins, which could also result in a neutral effect on
ancer risk.
tudy limitations. There are a number of limitations
nherent in the trial-level data analyses presented here. Use
f individual patient data would provide a more robust
nalysis in a variety of ways. Analysis of differences in
DL-C between patients in the same trial arm might reveal
ssociations that are masked by the use of trial level means.
ith individual patient data one can better account for
otential residual confounding that might remain in the
urrent analysis. Individual patient data would also allow for
etter standardization of interventions (statin type and
osage) and outcomes (definitions of incident cancer),
inimize selective reporting of cancer rates, incorporate
npublished data on longer follow-up, model individual
atient risks, and perform time-to-event analyses (28–30).
n the absence of individual patient data, the possibility that
ancers that developed during the course of the study caused
ower LDL-C, rather than vice versa, could not be ad-
ressed. An additional weakness of relying on trial level data
s the lack of standardized adjudication of newly diagnosed
ancer. Indeed, newly diagnosed cancer was not reported in
everal of the large randomized statin trials including recent
rials of intensive statin therapy, introducing the possibility
f selection bias. Finally, the location of cancer was not
onsistently reported across the trials, and, hence, whether
tatins may affect the risk of specific forms of cancer without
ffecting overall cancer risk could not be determined.
onclusions
he previously reported association of low levels of on-
reatment LDL-C and incident cancer, confirmed here, is
ot driven by statins, and statin therapy, despite producing
arked reductions in LDL-C, is not associated with an
ncreased risk of cancer. Further studies are needed to
alidate these findings, particularly with longer durations of
ollow-up.
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